TORL BioTherapeutics closed an oversubscribed $158M Series B-2 financing round to advance clinical development of its novel antibody-drug conjugate oncology pipeline.

Apr 10, 2024•over 1 year ago

Amount Raised

$158 Million

Round Type

series b

Culver CityBiotechnologyHealth Care

Description

TORL BioTherapeutics has closed an oversubscribed $158M Series B-2 financing round, with the proceeds intended for advancing the clinical development of its novel antibody-drug conjugate oncology pipeline.

Company Information

Company

TORL BioTherapeutics

Location

Culver City, California, United States

About

TORL BioTherapeutics is building a preeminent biopharmaceutical company dedicated to the discovery, development, and commercialization of antibody-based therapies to improve and extend the lives of people with cancer worldwide. Through a strategic partnership with the Slamon Research Lab at UCLA, TORL has exclusive development and commercial rights to a large program of biologics-based drugs for promising, and novel cancer targets.

Related People

3 contacts

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

TORL BioTherapeutics closed an oversubscribed $158M Series B-2 financing round to advance clinical development of its novel antibody-drug conjugate oncology pipeline.

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information